Efficacy and safety of IL-23 inhibitors in the treatment of moderate to severe ulcerative colitis: a meta-analysis based on randomized controlled trials
IL-23p19 inhibitors are effective and well tolerated in inducing and maintaining remission in patients with moderate to severe UC, including those with prior treatment failure. These findings support their use as a valuable therapeutic option in the evolving management landscape of UC.
Authors
- Xiangcheng Fan (ORCID: https://orcid.org/0000-0001-9563-9701)
- Hong Liang (ORCID: https://orcid.org/0000-0002-0579-8651)
- Leimin Sun (ORCID: https://orcid.org/0000-0001-7269-8258)
- Minyang He
Institutions
- Sir Run Run Shaw Hospital (CN)
- Tongde Hospital of Zhejiang Province (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-12-04
- DOI
- https://doi.org/10.3389/fmed.2025.1724448
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00